Aileron Therapeutics Inc (NAS:ALRN)

$ 2.87 0.03 (1.06%) Market Cap: 61.96 Mil Enterprise Value: 44.70 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 42/100

Aileron Therapeutics Inc M&A Call Transcript
Oct 31, 2023
Aileron Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual)- Pre-recorded Transcript
Sep 12, 2022
Aileron Therapeutics Inc Phase 1b Non-Small Cell Lung Cancer Interim Analysis Conference Call Transcript
Jun 29, 2022
Aileron Therapeutics Inc at Emerging Growth Conference Transcript
Jan 05, 2022
Aileron Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Q3 2019 Aileron Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$10.4 (-7.70%)

Earnings

Aileron Therapeutics Inc at Emerging Growth Conference Transcript

Jan 05, 2022 / 05:45PM GMT

Release Date Price: $11.2 (-7.27%)

Transcript

Ana Berry

Emerging Growth Conference - Moderator

Welcome back, everyone. Next up, we have Aileron Therapeutics, Inc. It trades on the NASDAQ under the symbol ALRN and is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. Please welcome its CEO, Manuel Aivado. Welcome, Manuel.

Manuel Aivado

Aileron Therapeutics, Inc. - CEO

Thank you, Ana. Thanks for the invite. Pleasure to be here. As Ana said, my name is Manuel Aivado, and I'm the President and CEO of Aileron Therapeutics. By background, I'm a medical oncologist with 25 years' experience in treating patients as well as developing drugs in the drug developing industry.

In the coming presentation, I will be making forward-looking statements as stated here on the slides that can be found on our website. And if I had to summarize the entire story of our company in one slide, this would be the slide.

What we do at Aileron is that we aspire to transform chemotherapy. We want to make chemotherapy a well

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.